Single-cell dosimetry for radioimmunotherapy of B-cell lymphoma patients with special reference to leukemic spread.

AIMS Many lymphoma patients have both macroscopic tumors and single-cell manifestations of their disease. Treatment efficacy could, therefore, depend on the radionuclide used. The aim of this study was to investigate dosimetry at a cellular level for three isotopes of radioiodine. METHODS Cells were assumed to be spherical with radii of 6.35, 7.7, and 9.05 microm corresponding to the dimensions of the Raji cells. The radius of the nucleus was assumed to be 75% of the cellular radius. The electron energies were 18, 28, and 190 keV, corresponding to the mean electron energy per decay for (125)I, (123)I, and (131)I, respectively. S-values for different activity distributions were simulated using Monte Carlo and dose-volume histograms as well as absorbed doses, and absorbed dose rates were calculated. RESULTS (125)I gives the highest absorbed dose (approximately 4-40 times that of (131)I), whereas (123)I will give the highest absorbed dose rate (approximately 100 times that of (131)I). Under the given assumptions, the absorbed dose at this level is more dependent on the size of the cells than on whether the radioimmunoconjugate is internalized. CONCLUSIONS This enquiry showed that both (123)I and (125)I have greater potential than (131)I for the treatment of leukemic spread in patients with lymphoma.

[1]  Francis A Cucinotta,et al.  A Complete Dielectric Response Model for Liquid Water: A Solution of the Bethe Ridge Problem , 2005, Radiation research.

[2]  Richard L Wahl,et al.  131I-tositumomab therapy as initial treatment for follicular lymphoma. , 2005, The New England journal of medicine.

[3]  T. Illidge,et al.  Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. , 2004, Blood.

[4]  Michael G Stabin,et al.  PHYSICAL MODELS AND DOSE FACTORS FOR USE IN INTERNAL DOSE ASSESSMENT , 2003, Health physics.

[5]  K. Karava,et al.  Monte Carlo simulation of the energy loss of low-energy electrons in liquid water. , 2003, Physics in medicine and biology.

[6]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Goldenberg,et al.  Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  Kostas Kostarelos,et al.  A Monte Carlo track structure code for electrons (~10 eV-10 keV) and protons (~0.3-10 MeV) in water: partitioning of energy and collision events , 2000 .

[9]  M. Béhé,et al.  Therapeutic advantages of Auger electron- over β-emitting radiometals or radioiodine when conjugated to internalizing antibodies , 2000, European Journal of Nuclear Medicine.

[10]  B. Cheson,et al.  Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  G. Griffiths,et al.  Cytotoxicity with Auger electron‐emitting radionuclides delivered by antibodies , 1999, International journal of cancer.

[12]  G. Griffiths,et al.  Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing D-amino acids. , 1999, Bioconjugate chemistry.

[13]  G. Griffiths,et al.  Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. , 1996, The Biochemical journal.

[14]  A. Nahum.  Microdosimetry and radiocurability: modelling targeted therapy with -emitters , 1996 .

[15]  M. Kaminski,et al.  Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Wheldon,et al.  Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  D. Goldenberg,et al.  Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma. , 1994, Hybridoma.

[18]  A. Scott,et al.  Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Howell.  The MIRD Schema: from organ to cellular dimensions. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  A. Farr,et al.  Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. , 1989, Cancer research.

[21]  R. R. Robinson,et al.  Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. , 1987, Journal of immunology.

[22]  E. Cavallin-ståhl,et al.  Flow cytometric light chain analysis of peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. , 1985, British Journal of Cancer.

[23]  Christophe Champion,et al.  Calculation of electron dose to target cells in a complex environment by Monte Carlo code “CELLDOSE” , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  Hooshang Nikjoo,et al.  The Effect of Model Approximations on Single-Collision Distributions of Low-Energy Electrons in Liquid Water , 2005, Radiation research.

[25]  S. Rodenhuis,et al.  Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody , 2005, Cancer Immunology, Immunotherapy.

[26]  G. Griffiths,et al.  Improved iodine radiolabels for monoclonal antibody therapy. , 2003, Cancer research.

[27]  A. Osterborg,et al.  Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. , 2001, The hematology journal : the official journal of the European Haematology Association.

[28]  E. Montserrat,et al.  Chronic lymphocytic leukaemia/small lymphocytic leukaemia. , 2001 .

[29]  T. Budinger,et al.  MIRD cellular S. values : self-absorbed dose per unit cumulated activity for selected radionuclides and monoenergetic electron and alpha particle emitters incorporated into different cell compartments , 1997 .

[30]  A. Nahum.  Microdosimetry and radiocurability: modelling targeted therapy with beta-emitters. , 1996, Physics in medicine and biology.

[31]  Thomas F. Budinger,et al.  MIRD primer for absorbed dose calculations , 1988 .